411 results on '"Casali, P. G."'
Search Results
2. Ethical issues in oncology practice: a qualitative study of stakeholders’ experiences and expectations
3. Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis
4. Shortcuts in Cosmological Branes
5. Brane World Cosmological Perturbations
6. When does a new sarcoma exist?
7. Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
8. Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard?
9. Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303
10. Sleep-like cortical OFF-periods disrupt causality and complexity in the brain of unresponsive wakefulness syndrome patients
11. Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
12. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database
13. Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection
14. Mode of action of trabectedin in myxoid liposarcomas
15. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper
16. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial
17. Erratum to: Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group
18. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma
19. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†
20. An ESMO-EORTC position paper on the EU clinical trials regulation and EMAʼs transparency policy: making European research more competitive again
21. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult
22. Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience
23. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST)
24. Surgical Technique, Morbidity, and Outcome of Primary Retroperitoneal Sarcoma Involving Inferior Vena Cava
25. Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution
26. Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution
27. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
28. Risks of the new EU Data protection regulation: an ESMO position paper endorsed by the European oncology community
29. Rare cancers: work in progress in Europe
30. Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment
31. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm—a position paper from the Italian and the French Sarcoma Group
32. Time course of adverse events in the phase III GRID study of regorafenib in patients with metastatic gastrointestinal stromal tumors (GIST): ID 013
33. Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes: ID 011
34. Results from a phase III trial (GRID) evaluating regorafenib (REG) in metastatic gastrointestinal stromal tumour (GIST): Subgroup analysis of outcomes based on pretreatment characteristics: ID 010
35. Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial: ID 012
36. The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO)
37. Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution
38. Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure
39. Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution
40. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients
41. Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity
42. Shortcuts in Cosmological Branes
43. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution
44. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall
45. Sensory evaluation of fabric touch by free modulus magnitude estimation
46. Effect of fabric sound and touch on human subjective sensation
47. Sunitinib malate in solitary fibrous tumor (SFT)
48. Adjuvant therapy in primary GIST: state-of-the-art
49. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas
50. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.